Oramed Pharmaceuticals Inc (ORMP)

[venturecapp]

Oramed Patent Being Granted in China for Oral Administration of Proteins

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).